BNTX Quote, Financials, Valuation and Earnings

Autolus Therapeutics PLC has a net margin of -227.46% compared to BioNTech SE's net margin of -781.13%. BioNTech SE's return on equity of -3.91% beat Autolus Therapeutics PLC's return on equity of -49.92%.

BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 322.99%. Given that Autolus Therapeutics PLC has higher upside potential than BioNTech SE, analysts believe Autolus Therapeutics PLC is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.594%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are larger than Autolus Therapeutics PLC quarterly revenues of $9M. BioNTech SE's net income of -$437.5M is lower than Autolus Therapeutics PLC's net income of -$70.2M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -227.46% compared to BioNTech SE's net margin of -907.48%. BioNTech SE's return on equity of -3.91% beat Moderna's return on equity of -29.23%.

BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 72.1%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are larger than Moderna quarterly revenues of $107M. BioNTech SE's net income of -$437.5M is higher than Moderna's net income of -$971M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus 3.43x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -227.46% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -3.91% beat NuCana PLC's return on equity of --.

BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 72373.87%. Given that NuCana PLC has higher upside potential than BioNTech SE, analysts believe NuCana PLC is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.98%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are larger than NuCana PLC quarterly revenues of --. BioNTech SE's net income of -$437.5M is lower than NuCana PLC's net income of -$3.1M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -227.46% compared to BioNTech SE's net margin of 82.81%. BioNTech SE's return on equity of -3.91% beat Novavax's return on equity of --.

BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Novavax has an analysts' consensus of $14.67 which suggests that it could grow by 103.7%. Given that Novavax has higher upside potential than BioNTech SE, analysts believe Novavax is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $192.3M, which are smaller than Novavax quarterly revenues of $626.3M. BioNTech SE's net income of -$437.5M is lower than Novavax's net income of $518.6M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax's PE ratio is 2.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus 0.98x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.